Endothelial dysfunction is one of the earliest indicators of cardiovascular (CV) dysfunction, and its evaluation would be of considerable importance to stratify CV risk of many diseases and to assess the efficacy of atheroprotective treatments. Flow-mediated dilation is the most widely used method to study endothelial function. However, it is operator-dependent and can be influenced by physiological variations. Circulating biomarkers are a promising alternative. Due to the complexity of endothelial function, many of the biomarkers studied do not provide consistent information about the endothelium when measured alone. New circulating markers are being explored and some of them are thought to be suitable for the clinical setting. In this review, we focus on novel biomarkers of endothelial dysfunction, particularly endothelial microparticles, endocan, and endoglin, and discuss whether they fulfill the criteria to be applied in clinical practice.
DaiberAStevenSWeberA, et al.Targeting vascular (endothelial) dysfunction. Br J Pharmacol. 2017;174:1591–619.
2.
VermaSBuchananMRAndersonTJ. Endothelial function testing as a biomarker of vascular disease. Circulation. 2003;108:2054–9.
3.
BonettiPOLermanLOLermanA. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23:168–75.
4.
DeanfieldJEHalcoxJPRabelinkTJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115:1285–95.
5.
Castro-FerreiraRCardosoRLeite-MoreiraAMansilhaA. The role of endothelial dysfunction and inflammation in chronic venous disease. Ann Vasc Surg. 2018;46:380–93.
6.
VermaSAndersonTJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002;105:546–9.
7.
WalczakMSurajJKusKKijAZakrzewskaAChlopickiS. Towards a comprehensive endothelial biomarkers profiling and endothelium-guided pharmacotherapy. Pharmacol Rep. 2015;67:771–7.
8.
Kuvin JeffreyTKaras RichardH. Clinical utility of endothelial function testing. Circulation. 2003;107:3243–7.
9.
AndersonTJGerhardMDMeredithIT, et al.Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol. 1995;75:71b–4b.
10.
BaltaSMikhailidisDPDemirkolSOzturkCCelikTIyisoyA. Endocan: a novel inflammatory indicator in cardiovascular disease?Atherosclerosis. 2015;243:339–43.
11.
HarrisRANishiyamaSKWrayDWRichardsonRS. Ultrasound assessment of flow-mediated dilation. Hypertension. 2010;55:1075–85.
12.
RasRTStreppelMTDraijerRZockPL. Flow-mediated dilation and cardiovascular risk prediction: a systematic review with meta-analysis. Int J Cardiol. 2013;168:344–51.
13.
HamburgNMBenjaminEJ. Assessment of endothelial function using digital pulse amplitude tonometry. Trends Cardiovasc Med. 2009;19:6–11.
14.
GiffordJRRichardsonRS. CORP: ultrasound assessment of vascular function with the passive leg movement technique. J Appl Physiol. 2017;123:1708–20.
15.
WangXSYangWLuoTWangJMJingYY. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers. 2015;19:124–7.
16.
BlannAD. A reliable marker of vascular function: does it exist?Trends Cardiovasc Med. 2015;25:588–91.
17.
KumarSWilliamsDSurSWangJYJoH. Role of flow-sensitive microRNAs and long noncoding RNAs in vascular dysfunction and atherosclerosis. Vascul Pharmacol. 2019;114:76–92.
18.
MenghiniRCasagrandeVFedericiM. MicroRNAs in endothelial senescence and atherosclerosis. J Cardiovasc Transl Res. 2013;6:924–30.
19.
ConstansJConriC. Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta. 2006;368:33–47.
20.
PaulusPJenneweinCZacharowskiK. Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis?Biomarkers. 2011;16:S11–21.
21.
SkibstedSJonesAEPuskarichMA, et al.Biomarkers of endothelial cell activation in early sepsis. Shock. 2013;39:427–32.
22.
SchuetzPPlebaniM. Can biomarkers help us to better diagnose and manage sepsis?Diagnosis (Berl). 2015;2:81–7.
23.
FangYLiCShaoRYuHZhangQ. The role of biomarkers of endothelial activation in predicting morbidity and mortality in patients with severe sepsis and septic shock in intensive care: a prospective observational study. Thromb Res. 2018;171:149–54.
24.
HsiaoSYKungCTTsaiNW, et al.Concentration and value of endocan on outcome in adult patients after severe sepsis. Clin Chim Acta. 2018;483:275–80.
25.
MeigsJBHuFBRifaiNMansonJE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA. 2004;291:1978–86.
26.
ChenJHammLLMohlerER, et al.Interrelationship of multiple endothelial dysfunction biomarkers with chronic kidney disease. PLoS One. 2015;10:e0132047.
27.
ChongAYBlannADPatelJFreestoneBHughesELipGY. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation. 2004;110:1794–8.
28.
NozakiTSugiyamaSKogaH, et al.Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J Am Coll Cardiol. 2009;54:601–8.
29.
BerckmansRJNieuwlandRBoingANRomijnFPHackCESturkA. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost. 2001;85:639–46.
30.
AlexandruNBadilaEWeissECochiorDStepienEGeorgescuA. Vascular complications in diabetes: microparticles and microparticle associated microRNAs as active players. Biochem Biophys Res Commun. 2016;472:1–10.
31.
SantilliFMarchisioMLanutiPBoccatondaAMisciaSDaviG. Microparticles as new markers of cardiovascular risk in diabetes and beyond. Thromb Haemost. 2016;116:220–34.
32.
Dignat-GeorgeFBoulangerCM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol. 2011;31:27–33.
33.
TheryCOstrowskiMSeguraE. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009;9:581–93.
34.
HeijnenHFSchielAEFijnheerRGeuzeHJSixmaJJ. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood. 1999;94:3791–9.
35.
LekakisJAbrahamPBalbariniA, et al.Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur J Cardiovasc Prev Rehabil. 2011;18:775–89.
36.
YongPJKohCHShimWS. Endothelial microparticles: missing link in endothelial dysfunction?Eur J Prev Cardiol. 2013;20:496–512.
37.
FavrettoGCunhaRSDDalboniMA, et al.Endothelial microparticles in uremia: biomarkers and potential therapeutic targets. Toxins. 2019;11:267.
38.
LacroixRRobertSPonceletPDignat-GeorgeF. Overcoming limitations of microparticle measurement by flow cytometry. Semin Thromb Hemost. 2010;36:807–18.
39.
van der PolEHoekstraAGSturkAOttoCvan LeeuwenTGNieuwlandR. Optical and non-optical methods for detection and characterization of microparticles and exosomes. J Thromb Haemost. 2010;8:2596–607.
40.
MezentsevAMerksRMO’RiordanE, et al.Endothelial microparticles affect angiogenesis in vitro: role of oxidative stress. Am J Physiol Heart Circ Physiol. 2005;289:H1106–14.
41.
JimenezJJJyWMauroLMHorstmanLLSoderlandCAhnYS. Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activation. Br J Haematol. 2003;123:896–902.
42.
BrodskySVZhangFNasjlettiAGoligorskyMS. Endothelium-derived microparticles impair endothelial function in vitro. Am J Physiol Heart Circ Physiol. 2004;286:H1910–5.
43.
van IersselSHHoymansVYVan CraenenbroeckEM, et al.Endothelial microparticles (EMP) for the assessment of endothelial function: an in vitro and in vivo study on possible interference of plasma lipids. PLoS One. 2012;7:e31496.
44.
YuanaYOosterkampTHBahatyrovaS, et al.Atomic force microscopy: a novel approach to the detection of nanosized blood microparticles. J Thromb Haemost. 2010;8:315–23.
45.
Montoro-GarciaSShantsilaETappLD, et al.Small-size circulating microparticles in acute coronary syndromes: relevance to fibrinolytic status, reparative markers and outcomes. Atherosclerosis. 2013;227:313–22.
46.
ZwickerJI. Tissue factor-bearing microparticles and cancer. Semin Thromb Hemost. 2008;34:195–8.
FreyssinetJMTotiF. Membrane microparticle determination: at least seeing what’s being sized!J Thromb Haemost. 2010;8:311–4.
49.
AmabileNBoulangerCM. Circulating microparticle levels in patients with coronary artery disease: a new indicator of vulnerability?Eur Heart J. 2011;32:1958–60.
FischerA-MDuvalAHelleyD, et al.Endothelial dysfunction in systemic lupus patients with low disease activity: evaluation by quantification and characterization of circulating endothelial microparticles, role of anti-endothelial cell antibodies. Rheumatology. 2010;49:1049–55.
52.
JimenezJJJyWMauroLMSoderlandCHorstmanLLAhnYS. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res. 2003;109:175–80.
53.
AmabileNHeissCRealWM, et al.Circulating endothelial microparticle levels predict hemodynamic severity of pulmonary hypertension. Am J Respir Crit Care Med. 2008;177:1268–75.
54.
NozakiTSugiyamaSSugamuraK, et al.Prognostic value of endothelial microparticles in patients with heart failure. Eur J Heart Fail. 2010;12:1223–8.
55.
SongRChouYIKongJ, et al.Association of endothelial microparticle with NO, eNOS, ET-1, and fractional flow reserve in patients with coronary intermediate lesions. Biomarkers. 2015;20:429–35.
56.
JungKHChuKLeeST, et al.Circulating endothelial microparticles as a marker of cerebrovascular disease. Ann Neurol. 2009;66:191–9.
57.
LeeS-TChuKJungK-H, et al.Circulating CD62E+ microparticles and cardiovascular outcomes. PLoS One. 2012;7:e35713.
58.
TsimermanGRoguinABacharAMelamedEBrennerBAharonA. Involvement of microparticles in diabetic vascular complications. Thromb Haemost. 2011;106:310–21.
59.
RautouPEVionACAmabileN, et al.Microparticles, vascular function, and atherothrombosis. Circ Res. 2011;109:593–606.
60.
MesriMAltieriDC. Endothelial cell activation by leukocyte microparticles. J Immunol. 1998;161:4382–7.
61.
BoulangerCMScoazecAEbrahimianT, et al.Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation. 2001;104:2649–52.
62.
AmabileNGuerinAPLeroyerA, et al.Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol. 2005;16:3381–8.
63.
BarryOPPraticoDSavaniRCFitzGeraldGA. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Clin Invest. 1998;102:136–44.
64.
CombesVSimonACGrauGE, et al.In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest. 1999;104:93–102.
65.
MallatZBenamerHHugelB, et al.Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation. 2000;101:841–3.
66.
Bernal-MizrachiLJyWJimenezJJ, et al.High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J. 2003;145:962–70.
67.
MinPKKimJYChungKH, et al.Local increase in microparticles from the aspirate of culprit coronary arteries in patients with ST-segment elevation myocardial infarction. Atherosclerosis. 2013;227:323–8.
68.
BoulangerCMAmabileNTedguiA. Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease. Hypertension. 2006;48:180–6.
69.
PisetskyDSUllalAJGauleyJNingTC. Microparticles as mediators and biomarkers of rheumatic disease. Rheumatology (Oxford). 2012;51:1737–46.
70.
MobarrezFAntoniewiczLBossonJAKuhlJPisetskyDSLundbäckM. The effects of smoking on levels of endothelial progenitor cells and microparticles in the blood of healthy volunteers. PLoS One. 2014;9:e90314.
71.
EspositoKCiotolaMSchisanoB, et al.Endothelial microparticles correlate with endothelial dysfunction in obese women. J Clin Endocrinol Metab. 2006;91:3676–9.
72.
ParkerBAl-HusainAPembertonP, et al.Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus. Ann Rheum Dis. 2014;73:1144–50.
73.
BartoloniEAlunnoABistoniO, et al.Characterization of circulating endothelial microparticles and endothelial progenitor cells in primary Sjögren’s syndrome: new markers of chronic endothelial damage?Rheumatology (Oxford). 2015;54:536–44.
74.
BroganPAShahVBrachetC, et al.Endothelial and platelet microparticles in vasculitis of the young. Arthritis Rheum. 2004;50:927–36.
75.
BernardSLoffroyRSérusclatA, et al.Increased levels of endothelial microparticles CD144 (VE-cadherin) positives in type 2 diabetic patients with coronary noncalcified plaques evaluated by multidetector computed tomography (MDCT). Atherosclerosis. 2009;203:429–35.
76.
JungKHChuKLeeST, et al.Risk of macrovascular complications in type 2 diabetes mellitus: endothelial microparticle profiles. Cerebrovasc Dis. 2011;31:485–93.
77.
PrestonRAJyWJimenezJJ, et al.Effects of severe hypertension on endothelial and platelet microparticles. Hypertension. 2003;41:211–7.
78.
BoulangerCMAmabileNGuerinAP, et al.In vivo shear stress determines circulating levels of endothelial microparticles in end-stage renal disease. Hypertension. 2007;49:902–8.
79.
HuSSZhangHGZhangQJXiuRJ. CD51+ endothelial microparticles as a biomarker of endothelial dysfunction in obese patients with hypertension. Endocrine. 2015;49:283–5.
80.
AgouniALagrue-Lak-HalAHDucluzeauPH, et al.Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. Am J Pathol. 2008;173:1210–9.
81.
HelalODefoortCRobertS, et al.Increased levels of microparticles originating from endothelial cells, platelets and erythrocytes in subjects with metabolic syndrome: relationship with oxidative stress. Nutr Metab Cardiovasc Dis. 2011;21:665–71.
82.
JiaLFanJCuiW, et al.Endothelial cell-derived microparticles from patients with obstructive sleep apnea hypoxia syndrome and coronary artery disease increase aortic endothelial cell dysfunction. Cell Physiol Biochem. 2017;43:2562–70.
83.
FanYWangLLiYYinZXuZWangC. Quantification of endothelial microparticles on modified cytometric bead assay and prognosis in chest pain patients. Circ J. 2014;78:206–14.
84.
WernerNWassmannSAhlersPKosiolSNickenigG. Circulating CD31+/annexin V+ apoptotic microparticles correlate with coronary endothelial function in patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2006;26:112–6.
85.
SinningJMLoschJWalentaKBohmMNickenigGWernerN. Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J. 2011;32:2034–41.
86.
SabatierFDarmonPHugelB, et al.Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes. 2002;51:2840–5.
87.
KogaHSugiyamaSKugiyamaK, et al.Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2005;45:1622–30.
88.
TushuizenMENieuwlandRRustemeijerC, et al.Elevated endothelial microparticles following consecutive meals are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care. 2007;30:728–30.
89.
FengBChenYLuoYChenMLiXNiY. Circulating level of microparticles and their correlation with arterial elasticity and endothelium-dependent dilation in patients with type 2 diabetes mellitus. Atherosclerosis. 2010;208:264–9.
90.
ChenYFengBLiXNiYLuoY. Plasma endothelial microparticles and their correlation with the presence of hypertension and arterial stiffness in patients with type 2 diabetes. J Clin Hypertens (Greenwich). 2012;14:455–60.
91.
CheifetzSBellonTCalesC, et al.Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem. 1992;267:19027–30.
92.
BurrowsFJDerbyshireEJTazzariPL, et al.Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res. 1995;1:1623–34.
93.
SantibanezJFQuintanillaMBernabeuC. TGF-beta/TGF-beta receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2011;121:233–51.
94.
LastresPLetamendiaAZhangH, et al.Endoglin modulates cellular responses to TGF-beta 1. J Cell Biol. 1996;133:1109–21.
95.
PardaliEGoumansMJTen DijkeP. Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends Cell Biol. 2010;20:556–67.
96.
JerkicMRodriguez-BarberoAPrietoM, et al.Reduced angiogenic responses in adult endoglin heterozygous mice. Cardiovasc Res. 2006;69:845–54.
97.
Lopez-NovoaJMBernabeuC. The physiological role of endoglin in the cardiovascular system. Am J Physiol Heart Circ Physiol. 2010;299:H959–74.
98.
BellonTCorbiALastresP, et al.Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol. 1993;23:2340234–5.
99.
GoumansMJTen DijkeP. TGF-beta signaling in control of cardiovascular function. Cold Spring Harb Perspect Biol. 2018;10:a022210.
100.
BlancoFJGrandeMTLangaC, et al.S-endoglin expression is induced in senescent endothelial cells and contributes to vascular pathology. Circ Res. 2008;103:1383–92.
101.
BernabeuCConleyBAVaryCPH. Novel biochemical pathways of endoglin in vascular cell physiology. J Cell Biochem. 2007;102:1375–88.
102.
SantibanezJFLetamendiaAPerez-BarriocanalF, et al.Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signaling. J Cell Physiol. 2007;210:456–68.
103.
TorsneyECharltonRParumsDCollisMArthurHM. Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res. 2002;51:464–70.
104.
TianFZhouAXSmitsAM, et al.Endothelial cells are activated during hypoxia via endoglin/ALK-1/SMAD1/5 signaling in vivo and in vitro. Biochem Biophys Res Commun. 2010;392:283–8.
105.
ten DijkePGoumansMJPardaliE. Endoglin in angiogenesis and vascular diseases. Angiogenesis. 2008;11:79–89.
106.
ConleyBASmithJDGuerrero-EsteoMBernabeuCVaryCP. Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis. 2000;153:323–35.
107.
PiaoMTokunagaO.Significant expression of endoglin (CD105), TGFbeta-1 and TGFbeta R-2 in the atherosclerotic aorta: an immunohistological study. J Atheroscler Thromb. 2006;13:82–9.
108.
LiCGBethellHWilsonPBBhatnagarDWalkerMGKumarS.The significance of CD105, TGFbeta and CD105/TGFbeta complexes in coronary artery disease. Atherosclerosis. 2000;152:249–56.
109.
WaltenbergerJAkyürekMLAurivilliusM, et al.Ischemia-induced transplant arteriosclerosis in the rat. Arterioscler Thromb Vasc Biol. 1996;16:1516–23.
110.
GraingerDKirschenlohrHMetcalfeJWeissbergPWadeDLawnR. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993;260:1655–8.
111.
RobertsABSpornMB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors. 1993;8:1–9.
112.
NachtigalPZemankova VecerovaLRathouskaJStraskyZ. The role of endoglin in atherosclerosis. Atherosclerosis. 2012;224:4–11.
113.
JerkicMRivas-ElenaJVPrietoM, et al.Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J. 2004;18:609–11.
114.
VenkateshaSToporsianMLamC, et al.Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642–9.
115.
JangYSChoiIH. Contrasting roles of different endoglin forms in atherosclerosis. Immune Netw. 2014;14:237–40.
116.
La SalaLPujadasGDe NigrisV, et al.Oscillating glucose and constant high glucose induce endoglin expression in endothelial cells: the role of oxidative stress. Acta Diabetol. 2015;52:505–12.
117.
IkemotoTHojoYKondoH, et al.Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases. Heart Vessels. 2012;27:344–51.
118.
BlannADWangJMWilsonPBKumarS. Serum levels of the TGF-beta receptor are increased in atherosclerosis. Atherosclerosis. 1996;120:221–6.
119.
StefoniSCiancioloGDonatiG, et al.Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int. 2002;61:324–35.
120.
JezkovaKRathouskaJNemeckovaI, et al.High levels of soluble endoglin induce a proinflammatory and oxidative-stress phenotype associated with preserved no-dependent vasodilatation in aortas from mice fed a high-fat diet. J Vasc Res. 2016;53:149–62.
121.
VitverovaBBlazickovaKNajmanovaI, et al.Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta. Atherosclerosis. 2018;271:15–25.
122.
VarejckovaMGallardo-VaraEVicenM, et al.Soluble endoglin modulates the pro-inflammatory mediators NF-kappaB and IL-6 in cultured human endothelial cells. Life Sci. 2017;175:52–60.
123.
Blázquez-MedelaAMGarcía-OrtizLGómez-MarcosMA, et al.Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med. 2010;8:8–86.
124.
EmeksizHCBideciADamarC, et al.Soluble endoglin level increase occurs prior to development of subclinical structural vascular alterations in diabetic adolescents. J Clin Res Pediatr Endocrinol. 2016;8:313–20.
125.
Cruz-GonzalezIPabonPRodriguez-BarberoA, et al.Identification of serum endoglin as a novel prognostic marker after acute myocardial infarction. J Cell Mol Med. 2008;12:955–61.
126.
BotPTGHoeferIESluijterJPG, et al.Increased expression of the transforming growth factor-β signaling pathway, endoglin, and early growth response-1 in stable plaques. Stroke. 2009;40:439–47.
127.
KapurNKHeffernanKSYunisAA, et al.Usefulness of soluble endoglin as a noninvasive measure of left ventricular filling pressure in heart failure. Am J Cardiol. 2010;106:1770–6.
128.
ZhangSMZuoLZhouQ, et al.Expression and distribution of endocan in human tissues. Biotech Histochem. 2012;87:172–8.
129.
SarrazinSAdamELyonM, et al.Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006;1765:25–37.
130.
CanpolatUKocyigitDYildirimA. Role of endothelial dysfunction and endocan in atherosclerosis: point of origin or end point? Angiology. 2016;0003319716654627.
131.
BechardDScherpereelAHammadH, et al.Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol. 2001;167:3099–106.
132.
RochaSFSchillerMJingD, et al.Esm1 modulates endothelial tip cell behavior and vascular permeability by enhancing VEGF bioavailability. Circ Res. 2014;115:581–90.
133.
LeeWKuSKKimSWBaeJS. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014;229:620–30.
134.
SunHZhangHLiK, et al.ESM-1 promotes adhesion between monocytes and endothelial cells under intermittent hypoxia. J Cell Physiol. 2019;234:1512–21.
135.
BaltaIBaltaSDemirkolS, et al.Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013;169:1066–70.
136.
BalanescuPLadaruABalanescuEVoiosuTBaicusCDanGA. Endocan, novel potential biomarker for systemic sclerosis: results of a pilot study. J Clin Lab Anal. 2016;30:368–73.
137.
IcliACureECureMC, et al.Endocan levels and subclinical atherosclerosis in patients with systemic lupus erythematosus. Angiology. 2016;67:749–55.
138.
MihajlovicDMLendakDFBrkicSV, et al.Endocan is useful biomarker of survival and severity in sepsis. Microvasc Res. 2014;93:92–7.
139.
ScherpereelADepontieuFGrigoriuB, et al.Endocan, a new endothelial marker in human sepsis. Crit Care Med. 2006;34:532–7.
140.
De Freitas CairesNGaudetAPortierLTsicopoulosAMathieuDLassalleP. Endocan, sepsis, pneumonia, and acute respiratory distress syndrome. Crit Care. 2018;22:280.
141.
GungorAPalabiyikSSBayraktutanZ, et al.Levels of endothelial cell-specific molecule-1 (ESM-1) in overt hypothyroidism. Endocr Res. 2016;41:275–80.
142.
AparciMIsilakZUzOYalcinMKucukU. Endocan and endothelial dysfunction. Angiology. 2015;66:488–9.
143.
KoseMEmetSAkpinarTS, et al.Serum endocan level and the severity of coronary artery disease: a pilot study. Angiology. 2015;66:727–31.
144.
ÇimenTEfeTHAkyelA, et al.Human endothelial cell-specific molecule-1 (endocan) and coronary artery disease and microvascular angina. Angiology. 2016;67:846–53.
145.
KundiHBalunACicekciogluH, et al.Admission endocan level may be a useful predictor for in-hospital mortality and coronary severity index in patients with ST-segment elevation myocardial infarction. Angiology. 2017;68:46–51.
146.
MusialowskaDZbrochEKoc-ZorawskaEMusialowskiPMalyszkoJ. Endocan concentration in patients with primary hypertension. Angiology. 2018;69:483–9.
147.
LvYZhangYShiW, et al.The association between endocan levels and subclinical atherosclerosis in patients with type 2 diabetes mellitus. Am J Med Sci. 2017;353:433–8.
148.
BalamirIAtesITopcuogluCTurhanT. Association of endocan, ischemia-modified albumin, and hsCRP levels with endothelial dysfunction in type 2 diabetes mellitus. Angiology. 2018;69:609–16.
149.
YilmazMISiriopolDSaglamM, et al.Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014;86:1213–20.
150.
AltintasNMutluLCAkkoyunDC, et al.Effect of CPAP on new endothelial dysfunction marker, endocan, in people with obstructive sleep apnea. Angiology. 2016;67:364–74.
151.
ZhaoTKechengYZhaoX, et al.The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease: a meta-analysis. Med (Baltimore). 2018;97:e13407.
152.
ArpaciDKarakeceETocogluAG, et al.Endocan, TGF-beta, and ADMA as risk factors for endothelial dysfunction and possible vascular disease in patients with subclinical hypothyroidism. Ann Clin Lab Sci. 2016;46:601–7.
153.
AğaçMTKahyaogluBAksoyMMNCinemreFBVatanMBGunduzY. Is endocan a biochemical marker for asymptomatic target organ damage in hypertensive patients?Anatol J Cardiol. 2019;21:76–82.
154.
DallioMMasaroneMCaprioGG, et al.Endocan serum levels in patients with non-alcoholic fatty liver disease with or without type 2 diabetes mellitus: a pilot study. J Gastrointestin Liver Dis. 2017;26:261–8.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
